BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Braveheart Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$19.21+0.50 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $142.19M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
3 of Braveheart Bio's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 8, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 8, 2026 | Sep 8, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 5, 2026 | Aug 7, 2026 | SEC EDGAR |